Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMW1OI6)

Drug Name
P32/98 Drug Info
Synonyms Isoleucine-thiazolidide; AC1OCFGS; MolPort-044-561-375
Indication
Disease Entry ICD 11 Status REF
Autism spectrum disorder 6A02 Phase 2 [1]
Cross-matching ID
PubChem CID
6918464
TTD Drug ID
DMW1OI6

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dipeptidyl peptidase 4 (DPP-4) TTDIGC1 DPP4_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Dipeptidyl peptidase 4 (DPP-4) DTT DPP4 4.995 4.926 7.852 8.358
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Autism spectrum disorder
ICD Disease Classification 6A02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dipeptidyl peptidase 4 (DPP-4) DTT DPP4 9.54E-01 -0.27 -1.85
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 2002 Apr;51(4):943-50.